Adapted from LIBTAYO Product Monograph 1
a Median duration of follow-up: metastatic CSCC: 8.1 months; locally
advanced CSCC: 10.2 months; combined CSCC: 8.9 months
b For patients with metastatic CSCC without externally visible
target lesions, ORR was determined by Response Evaluation Criteria
in Solid Tumors (RECIST 1.1). For patients with externally visible
target lesions (locally advanced CSCC and metastatic CSCC), ORR was
determined by a composite endpoint that integrated ICR assessments
of radiologic data (RECIST 1.1) and digital medical photography (WHO
criteria).1
c Only included patients with complete healing of prior cutaneous
involvement; locally advanced CSCC patients in study 1540 required
biopsy to confirm complete response.
d 41 of 51 responses were on-going at last assessment.
Adapted from LIBTAYO Product Monograph 1
• Patients followed for a median duration of 8.9 months (at time of data cut-off)1‡
CI: confidence interval; NR: not reached; +: denotes ongoing at
last assessment.
† Results are presented as a combined analysis of 26 CSCC patients
from Study 1423 and 82 patients from Study 1540.1
‡ Combined CSCC patients.
The following cases are examples of patients treated with LIBTAYO during the study and the visible changes in external CSSC lesions that resulted. They may not be representative of all patients.3
† Patient from the Phase 1 study (Study 1423) – may not be representative of all patients.
† Patient from the Phase 1 study (Study 1423) – may not be representative of all patients.
† Patient from the Phase 1 study (Study 1423) – may not be representative of all patients.
Learn about the safety and tolerability profile of LIBTAYO in patients with advanced CSCC.
Learn more
Learn the details behind Study 1423 and Study 1540, two clinical trials used to evaluate the efficacy and safety profile of LIBTAYO.
Learn more